Skip to main content
×
×
Home

The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing

  • Jacqueline Birks (a1)
Extract

The cholinesterase inhibitors (tacrine, donepezil, galantamine and rivastigmine) were the first drugs licensed for mild to moderate Alzheimer's disease (AD). Recently, the use of donepezil has been extended to severe AD. Tacrine was the first to be marketed, which, although beneficial in AD, shows a high incidence of adverse effects and is rarely used. It will not be discussed further. The cholinesterase inhibitors are widely prescribed and continue to be the first line in the treatment of AD. Considering the mode of action of the cholinesterase inhibitors it is not expected that they will alter the course of the disease, but they may help with some of the manifestations of dementia.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 2
Total number of PDF views: 10 *
Loading metrics...

Abstract views

Total abstract views: 95 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th February 2018. This data will be updated every 24 hours.